Retatrutide 12 mg

Mid-strength Retatrutide formulation commonly incorporated into advanced metabolism-support protocols.

Retatrutide represents the next generation of incretin-based research compounds. Unlike dual-agonists such as Tirzepatide, it targets three key receptors simultaneously: GLP-1, GIP, and Glucagon. This triple-agonist mechanism has been extensively documented in peer-reviewed literature for its interaction with metabolic signaling pathways and receptor cross-talk.

• Activates GLP-1, GIP, and Glucagon receptors simultaneously
• First compound designed with this triple-agonist mechanism
• Extended half-life suitable for weekly research protocols
• Well-documented in peer-reviewed scientific journals
• Stable compound suitable for in-vitro research protocols

For laboratory and in-vitro research use only. Not for human or animal use.